April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Preliminary Estimation and Validation of the Glaucoma Utility Index-Singapore.
Author Affiliations & Notes
  • Hla Myint Htoon
    Singapore Eye Research Inst, Singapore, Singapore
    Duke-NUS Graduate Medical School, Singapore, Singapore
  • Mani Baskaran
    Singapore Eye Research Inst, Singapore, Singapore
    Duke-NUS Graduate Medical School, Singapore, Singapore
  • Junxing Chay
    Duke-NUS Graduate Medical School, Singapore, Singapore
  • Ai T Aw
    Singapore National Eye Centre, Singapore, Singapore
  • Tin Aung
    Singapore National Eye Centre, Singapore, Singapore
    Yong Loo Lin School of Medicine,National University of Singapore, Singapore, Singapore
  • Ecosse L Lamoureux
    Singapore Eye Research Inst, Singapore, Singapore
    Duke-NUS Graduate Medical School, Singapore, Singapore
  • Eric A Finkelstein
    Duke-NUS Graduate Medical School, Singapore, Singapore
  • Footnotes
    Commercial Relationships Hla Htoon, None; Mani Baskaran, None; Junxing Chay, None; Ai T Aw, None; Tin Aung, None; Ecosse Lamoureux, None; Eric Finkelstein, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 179. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hla Myint Htoon, Mani Baskaran, Junxing Chay, Ai T Aw, Tin Aung, Ecosse L Lamoureux, Eric A Finkelstein; Preliminary Estimation and Validation of the Glaucoma Utility Index-Singapore.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):179. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To estimate glaucoma utility values from a Discrete Choice Experimental (DCE) questionnaire set and test the theoretical and convergent validity of this new glaucoma utility index developed in Singapore (GUI-S).

Methods: The GUI-S had seven validated dimensions namely central and near vision; lighting and glare; mobility; activities of daily living; eye discomfort; other glaucoma effects; and psychosocial effects. A preference based efficiently constructed experimental design for the 7 dimensions with three levels of difficulty (no difficulty; some difficulty and severe difficulty), was used to elicit responses from glaucoma patients at a tertiary eye hospital in Singapore. A conditional logistic regression was used to estimate the coefficients, and utility weights (GUI-S) were derived for a given glaucoma profile. A-priori coefficient movements were hypothesized to correlate with disease severity and a generic VAS (Visual Analogue Scale) was used to determine the theoretical and convergent validity parameters of the GUI-S, respectively.

Results: 70 primary glaucoma patients (72.9% with primary open angle) responses were collected: mean age 68.2 years (±9.1), female (27.1%), glaucoma severity; (48.6% mild, 34.3% moderate, 17.1% severe); and the majority were Chinese (94.3%). The significant estimated utility values comparing ‘no difficulty’ with ‘some/severe difficulty’ in each of the dimensions were: central near vision (0.13, p=0.001), lighting and glare (0.20, p<0.001), mobility (0.32, p<0.001), psychosocial dimensions (0.19, p<0.001). GUI-S values were negatively related with glaucoma severity (p= 0.04): 0.52 (± 0.28) for mild; 0.40 (±0.21) for moderate; 0.31 (±0.30) for severe. VAS values were also negatively associated with glaucoma severity (ANOVA, p=0.003): 0.78 (±0.18) for mild; 0.75 (± 0.24) for moderate; 0.52 (± 0.27) for severe.

Conclusions: GUI-S, based on responses elicited from an efficiently designed DCE questionnaire, showed sufficient convergent and theoretical validity with a generic health outcome (VAS) and glaucoma disease severity, respectively.

Keywords: 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower • 468 clinical research methodology  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×